A Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Novel PI3k Delta Inhibitor; and Ibrutinib or Bendamustine, in Patients With B-cell Malignancies.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Oct 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ublituximab (Primary) ; Umbralisib (Primary) ; Bendamustine; Ibrutinib
Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man
Sponsors TG Therapeutics Inc

Most Recent Events

01 Oct 2019 Status changed from active, no longer recruiting to completed.
30 Sep 2019 According to a TG Therapeutics Inc media release, data from this trial were published in Blood, the Journal of the American Society of Hematology.
30 Sep 2019 Results presented in the TG Therapeutics Inc media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight